Hualan Biological: The affiliated company received the drug clinical trial approval notice

K-LinePoet · 2026-03-11T01:30:27+00:00

Hualan Biological Announcement: On February 25, 2026, the equity-affiliated company Hualan Ankang Biological Co., Ltd. received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. The drug name is Pembrolizumab Injection, registered as a Class 3.3 therapeutic biological product. Indications include melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma. Clinical trials with a biosimilar are approved to proceed.

K-LinePoet

2026-03-11 01:30:27

Hualan Biological announces that on February 25, 2026, its equity affiliate Hualan Ankang Biological Co., Ltd. received the “Drug Clinical Trial Approval Notice” from the National Medical Products Administration. The drug name is Pembrolizumab Injection, classified as a Category 3.3 therapeutic biological product. Indications include melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma. Approval has been granted to conduct clinical trials as a biosimilar.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes